S-1/A: Cardiff Lexington Corporation Files Amendment No. 3 to Form S-1/A, Aiming for NYSE American/Nasdaq Uplisting

Cardiff Lexington Corporation files an amended registration statement for a proposed offering of 1,600,000 shares of common stock, contingent upon uplisting to NYSE American or Nasdaq.

Summary

• Cardiff Lexington Corporation has filed Amendment No. 3 to its Form S-1/A registration statement.
• The company is proposing an offering of 1,600,000 shares of common stock, with an estimated public offering price between $4.00 and $6.00 per share.
• The offering is contingent upon the company's uplisting to either the NYSE American or The Nasdaq Capital Market under the ticker symbol CDIX.
• The company intends to use the net proceeds from this offering for working capital and general corporate purposes, which could include future acquisitions.
• Following the offering, executive officers and directors are expected to control approximately 72.53% of the company's total voting power.
• The company's common stock is currently quoted on the OTC Pink Market under the symbol CDIX.
• The company operates primarily in the healthcare industry through its subsidiary Nova Ortho and Spine, and also owns a real estate company, Edge View Properties, Inc.
• For the year ended December 31, 2023, the company reported total revenue of $11,853,266 and a net income of $3,028,394.
• For the three months ended March 31, 2024, the company reported total revenue of $2,661,966 and a net loss of $283,104.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company achieved net income for the year ended December 31, 2023, it also reported a net loss for the three months ended March 31, 2024. The company is pursuing an uplisting and has growth strategies in place, but it also faces risks and challenges, including a going concern explanatory paragraph from its auditor.

Positives

• The company achieved net income of $3,028,394 for the year ended December 31, 2023, compared to a net loss in the previous year.
• The company's healthcare business is experiencing revenue growth, with $11,853,266 in revenue for the year ended December 31, 2023.
• The company is expanding its healthcare operations, with eleven facilities currently operating.
• The company is partially insulated from Medicare/Medicaid reimbursement pressures due to its focus on bodily injury and personal injury protection policies.

Negatives

• The company reported a net loss of $283,104 for the three months ended March 31, 2024.
• The company's eleven healthcare facilities are estimated to be operating at only 35% capacity as of March 31, 2024.
• The company's future success is dependent on its ability to obtain additional financing.
• The company's independent auditor included a going concern explanatory paragraph in its report for the year ended December 31, 2023.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• The company's acquisition strategy exposes it to substantial risk, including the failure to identify material problems during due diligence.
• The company may not be able to effectively integrate the businesses that it acquires.
• The market price of the company's common stock may be highly volatile.
• The company's officers and directors own a significant percentage of the outstanding voting securities, which could reduce the ability of minority stockholders to effect certain corporate actions.
• The company may not be able to satisfy [NYSE American/Nasdaq]'s listing requirements or maintain a listing of its common stock on [NYSE American/Nasdaq].
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects to maximize organic growth by deploying increased working capital to expand utilization at current locations, open additional locations, and may look at select synergistic acquisitions in the healthcare sector.

Industry Context

The document indicates that the company operates in the healthcare sector, which is subject to extensive and complex laws and regulations. The company also faces competition from other healthcare providers.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• The document mentions that the healthcare industry is highly competitive, and the company competes with other facilities that provide similar services.
• The document also notes that some competitors may have greater financial resources and offer a broader range of services.

Management Changes

Related Party Transactions

• The company obtained short-term advances from Daniel Thompson, the Chairman of the Board, that are non-interest bearing and due on demand.
• On August 25, 2023, the company issued a convertible promissory note in the principal amount of $5,000 to Alex Cunningham, our Chief Executive Officer.

Stakeholder Impact

• The offering could dilute the ownership of existing shareholders.
• The company's future performance will impact the value of its common stock.
• The company's ability to execute its business strategy will affect its stakeholders, including employees, customers, and suppliers.

Next Steps

• The company intends to apply for the listing of its common stock on [NYSE American/The Nasdaq Capital Market] under the symbol CDIX.
• The company intends to use the net proceeds from this offering for working capital and general corporate purposes, which could include future acquisitions.

Key Dates

Keywords

common stock, offering, acquisition, healthcare, preferred stock, convertible notes, uplisting, financial results, Cardiff Lexington, S-1/A